|February 18, 2004
DynPort Vaccine Company Selects Finjan's Mirage Solution to Provide Precise Control over FDA Regulated Processes and Documentation
|Digital Rights Management Tool to be Used for Conducting Research, Studies and Clinical Trials
|SAN JOSE, Calif., Feb. 18 /PRNewswire/ -- Finjan Software, the leading provider of proactive content security and management solutions for global companies, today announced that DynPort Vaccine Company LLC (DVC), a biopharmaceutical company focused on the development and licensure of biodefense vaccines, has licensed its MirageŽ digital rights management solution for process control and regulatory compliance with the Food and Drug Administration.
Finjan's Mirage solution will provide data integrity and security to DVC during the complex and demanding processes leading up to FDA licensure and will facilitate compliance with federally mandated privacy laws. Mirage secures, tracks and audits the provisioning and accessing of sensitive digital documents to protect important business operations, reduce legal liabilities and comply with industry regulations. It prevents unauthorized copying, printing, saving, forwarding and screen capturing of sensitive information without interrupting normal business processes. Mirage gives system administrators the ability to control and set policies for trusted users.
"Protecting sensitive research materials like clinical trial data from unauthorized use is important to every company in the biodefense industry," said DynPort Vaccine Company President Terry Irgens. "Mirage helps us comply with industry requirements and provides peace of mind without interrupting our daily work."
"Legislative requirements in the U.S. combined with government oversight, further encourages companies to take a critical look at their internal processes and policies, particularly companies in sensitive industries," said Shlomo Touboul, founder and CEO of Finjan Software. "Our Mirage solution provides organizations with a tool to track, trace and audit the flow of documents to minimize the risk of distributing sensitive information outside of pre-defined controls and reduce the potential for legal consequences."
DynPort Vaccine Company LLC (DVC) is a biopharmaceutical company dedicated to the development and licensure of safe and efficacious biodefense vaccines. DVC is a joint venture between Computer Sciences Corporation (NYSE: CSC - News), a leading information technology (IT) services company, and Porton International Inc., a leading vaccine development company focused on the development of biodefense vaccines. For more information about DVC, visit http://www.dynport.com.
Finjan Software is the leading provider of proactive content security solutions to global organizations. Exceeding the preliminary level of defense typically offered by reactive anti-virus software solutions, Finjan's Vital Security family of products proactively responds to changing, yet-to-be-created Internet security threats and closes the Window of Vulnerability. Finjan is recognized by analyst firm IDC as the leader in the worldwide malicious mobile code security market. For more information, visit http://www.finjan.com.
NOTE: Finjan, SurfinGate, SurfinGuard, and SurfinShield are registered trademarks of Finjan Software. Window of Vulnerability and Vital Security are trademarks of Finjan Software. Other trademarks in this document belong to their respective owners.
The Finjan Software products described in this document are protected by U.S. Patent No. 6092194, 6167520 and 6480962 and may be protected by other U.S. Patents, foreign patents, or pending applications.